Alprazolam Systematic (IUPAC) name 8-chloro-1-methyl-6-phenyl-4H-
Clinical data Trade names Xanax AHFS/Drugs.com MedlinePlus Pregnancy cat. D(US) Legal status POM (UK) Schedule IV (US) Routes Oral Pharmacokinetic data Bioavailability 80–90% Metabolism Hepatic, via Cytochrome P450 3A4 Half-life Immediate release: 11.2 hours,
Extended release: 10.7–15.8 hours
Excretion Renal Identifiers CAS number ATC code N05 PubChem DrugBank ChemSpider UNII KEGG ChEBI ChEMBL Chemical data Formula C17H13ClN4 Mol. mass 308.765 SMILES & (what is this?)
Alprazolam // (trade name Xanax, available among other generic names) is a short-acting anxiolytic of the benzodiazepine class of psychoactive drugs. Alprazolam, like other benzodiazepines, binds to specific sites on the GABAA gamma-amino-butyric acid receptor. Alprazolam is commonly used and FDA approved for the treatment of panic disorder, and anxiety disorders, such as generalized anxiety disorder (GAD) or social anxiety disorder (SAD). Alprazolam is available for oral administration in compressed tablet (CT) and extended-release capsule (XR) formulations. Alprazolam possesses anxiolytic, sedative, hypnotic, skeletal muscle relaxant, anticonvulsant, and amnestic properties.
Alprazolam has a fast onset of action and symptomatic relief. 90% of peak benefits are achieved within the first hour of using either preparation for panic disorder, and full peak benefits are achieved in 1.5 and 1.6 hours respectively. Peak benefits achieved for generalized anxiety disorder (GAD) may take up to a week. Tolerance does not appear to develop to the anxiolytic effects but may develop to the sedative effects within a couple of days. Withdrawal symptoms or rebound symptoms may occur after ceasing treatment abruptly following a few weeks or longer of steady dosing, and may necessitate a gradual dose reduction.
Alprazolam is the most prescribed, and the most misused benzodiazepine on the U.S. retail market. The potential for abuse is low  and is similar to that of other benzodiazepine drugs. Compared to the large number of prescriptions, relatively few individuals increase their dose on their own initiative or engage in drug-seeking behavior.  Alprazolam is classified as a schedule C IV controlled substance by the U.S. Drug Enforcement Agency (DEA).
- 1 Medical uses
- 2 Pregnancy and lactation
- 3 Contraindications
- 4 Adverse effects
- 5 Detection in body fluids
- 6 Pharmacology
- 7 Pharmacokinetics
- 8 Chemistry
- 9 History
- 10 Society and culture
- 11 References
- 12 External links
Alprazolam is primarily used to treat anxiety disorders, panic disorders, and nausea due to chemotherapy. The FDA label advises that the physician should periodically reassess the usefulness of the drug.
In the US alprazolam is FDA-approved for the treatment of panic disorder with or without agoraphobia. Alprazolam is effective in the relief of moderate to severe anxiety and panic attacks. Systematic clinical studies of effectiveness in treating panic disorder have been limited to 4 to 10 weeks. However, patients with panic disorder have been treated on an open basis for up to 8 months without apparent loss of benefit.
Alprazolam is recommended by the World Federation of Societies of Biological Psychiatry (WFSBP) for treatment resistant cases of panic disorder where there is no history of tolerance or dependence, as of 2002.
In the US alprazolam is FDA-approved for the management of anxiety disorders (a condition corresponding most closely to the APA Diagnostic and Statistical Manual DSM-III-R diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety associated with depression is responsive to alprazolam. Demonstrations of the effectiveness by systematic clinical study are limited to 4 months duration for anxiety disorder.
Long term users of alprazolam may develop depression.
Nausea due to chemotherapy
Pregnancy and lactation
Benzodiazepines cross the placenta, enter into the fetus and are also excreted with breast milk. The use of benzodiazepines during pregnancy or lactation has potential risks. The use of alprazolam in pregnancy is believed to be associated with congenital abnormalities. Diazepam and chlordiazepoxide have a better safety profile in pregnancy than alprazolam.
Women who are pregnant or are planning on becoming pregnant should avoid starting alprazolam. Use in the last trimester may cause fetal drug dependence and withdrawal symptoms in the post-natal period as well as neonatal flaccidity and respiratory problems. However, in long-term users of benzodiazepines abrupt discontinuation due to concerns of teratogenesis has a high risk of causing extreme withdrawal symptoms and a severe rebound effect of the underlying mental health disorder. Spontaneous abortions may also result from abrupt withdrawal of psychotropic medications including benzodiazepines.
Benzodiazepines, including alprazolam, are known to be excreted in human milk. Chronic administration of diazepam to nursing mothers has been reported to cause their infants to become lethargic and to lose weight.
Benzodiazepines require special precaution if used in children and in alcohol- or drug-dependent individuals. Particular care should be taken in pregnant or elderly patients, patients with substance abuse history, particularly alcohol dependence and patients with comorbid psychiatric disorders. Use of alprazolam should be avoided or carefully monitored by medical professionals in individuals with the following conditions: myasthenia gravis, acute narrow-angle glaucoma, severe liver deficiencies (e.g., cirrhosis), severe sleep apnea, pre-existing respiratory depression, marked neuromuscular respiratory weakness including unstable myasthenia gravis, acute pulmonary insufficiency, chronic psychosis, hypersensitivity or allergy to alprazolam or other drugs in the benzodiazepine class, borderline personality disorder (may induce suicidality and dyscontrol).
Like all central nervous system depressants, including alcohol, alprazolam in larger-than-normal doses can cause significant deterioration in alertness, combined with increased feelings of drowsiness, especially in those unaccustomed to the drug's effects. People driving or conducting activities that require vigilance should exercise caution in using alprazolam or any other depressant.
Elderly individuals should be cautious in the use of alprazolam due to the possibility of increased susceptibility to side-effects, especially loss of coordination and drowsiness.
Although the side-effect profile of alprazolam is, in general, benign, side-effects may occur in some patients and are more likely the higher the dosage taken. Some side-effects may disappear with continued treatment. If signs of an allergic reaction occur - such as hives; difficulty breathing; swelling of face, lips, tongue, or throat - medical attention should be sought immediately. Medical attention should also be sought immediately if signs of jaundice appear: yellowing of the skin or eyes. Other side-effects that may occur are as follows:
- Drowsiness, dizziness, lightheadedness, fatigue, unsteadiness and impaired coordination, vertigo
- Skin rash, respiratory depression, constipation
- Suicidal ideation (rare)
- Urinary retention (infrequent)
- Hallucinations (rare)
- Ataxia, slurred speech
- Anterograde amnesia and concentration problems
- Change in libido
- Dry mouth (infrequent)
- Jaundice (very rare)
Although unusual, if the following paradoxical reactions occur, the prescribing physician or other healthcare professional should be alerted and the medication gradually discontinued:
- Twitches and tremor
- Rage, hostility
- Mania, agitation, hyperactivity and restlessness
Food and drug interactions
Alprazolam is primarily metabolised via CYP3A4. Combining CYP3A4 inhibitors with alprazolam can lead to profound sedating effects. Cimetidine, erythromycin, fluoxetine, fluvoxamine, itraconazole, ketoconazole, nefazodone, propoxyphene, and ritonavir all interact with alprazolam leading to a delayed clearance of alprazolam, which may result in excessive accumulation of alprazolam. This may result in excessive sedation and other adverse effects associated with excessive intake of alprazolam.
Imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day. Combined oral contraceptive pills reduce the clearance of alprazolam, which may lead to increased plasma levels of alprazolam and accumulation.
Alcohol is one of the most important and common interactions. Alcohol and benzodiazepines such as alprazolam taken in combination have a synergistic effect on one another, which can cause severe sedation, behavioral changes, and intoxication. The more alcohol and alprazolam taken the worse the interaction. Combination of alprazolam with the herb kava can result in the development of a semi-comatose state. Hypericum conversely can lower the plasma levels of alprazolam and reduce its therapeutic effect.
Overdoses of alprazolam can be mild to severe depending on how much of the drug is taken and any other drugs that have been taken.
- Somnolence (sleepy state)
- Hypotension (low blood pressure)
- Hypoventilation (shallow breathing)
- Impaired motor functions
- Death (very rare)
In a study of deaths in Palm Beach County where the drug alprazolam was detected, approx. 50% of cases were attributed to poly-drug use (the combined toxicity of two or more drugs). The majority of these cases included either cocaine or methadone. Alprazolam alone caused only 1% of the deaths. These results indicate alprazolam has a very low incidence of causing death when taken alone.
Dependence and withdrawal
Alprazolam, like other benzodiazepines, binds to specific sites on the GABAA gamma-amino-butyric acid receptor. When bound to these sites, which are referred to as benzodiazepine receptors, it modulates the effect of GABA A receptors and, thus, GABAergic neurons. Long-term use causes adaptive changes in the benzodiazepine receptors, making them less sensitive to stimulation and less powerful in their effects.
Not all withdrawal effects are evidence of true dependence or withdrawal. Recurrence of symptoms such as anxiety may simply indicate that the drug was having its expected anti-anxiety effect and that, in the absence of the drug, the symptom has returned to pretreatment levels. If the symptoms are more severe or frequent, the patient may be experiencing a rebound effect due to the removal of the drug. Either of these can occur without the patient's actually being drug-dependent.
Alprazolam and other benzodiazepines may also cause the development of physical dependence, tolerance, and benzodiazepine withdrawal symptoms during rapid dose reduction or cessation of therapy after long-term treatment. There is a higher chance of withdrawal reactions if the drug is administered in a higher dosage than recommended, or if a patient stops taking the medication altogether without slowly allowing the body to adjust to a lower-dosage regimen.
In 1992, Romach and colleagues reported that dose escalation is not a characteristic of long-term alprazolam users, and that the majority of long-term alprazolam users change their initial pattern of regular use to one of symptom control only when required.
Some common symptoms of alprazolam discontinuation include malaise, weakness, insomnia, tachycardia, lightheadedness, and dizziness.
Patients taking a dosing regimen larger than 4 mg per day have an increased potential for dependence. This medication may cause withdrawal symptoms upon abrupt withdrawal or rapid tapering, which in some cases have been known to cause seizures. The discontinuation of this medication may also cause a reaction called rebound anxiety. Grand mal seizures have occurred after abrupt withdrawal after only short-term use. Therefore, even short-term users of alprazolam should taper off of their medication slowly to avoid serious withdrawal reactions including seizures.
In a 1983 study of patients who had taken long-acting benzodiazepines, e.g., clorazepate, for extended periods, the medications were stopped abruptly. Only 5% of patients who had been taking the drug for less than 8 months demonstrated withdrawal symptoms, but 43% of those who had been taking them for more than 8 months did. With alprazolam - a short-acting benzodiazepine - taken for 8 weeks, 35% of patients experienced significant rebound anxiety. To some degree, these older benzodiazepines are self-tapering.
The benzodiazepines diazepam (Valium) and oxazepam (Serepax) have been found to produce fewer withdrawal reactions than alprazolam (Xanax), temazepam (Restoril/Normison), or lorazepam (Temesta/Ativan). Factors that determine the risk of psychological dependence or physical dependence and the severity of the benzodiazepine withdrawal symptoms experienced during dose reduction of alprazolam include: dosage used, length of use, frequency of dosing, personality characteristics of the individual, previous use of cross-dependent/cross-tolerant drugs (alcohol or other sedative-hypnotic drugs), current use of cross-dependent/-tolerant drugs, use of other short-acting, high-potency benzodiazepines, and method of discontinuation.
Detection in body fluids
Alprazolam may be quantitated in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest or to assist in a medicolegal death investigation. Blood or plasma alprazolam concentrations are usually in a range of 10-100 μg/L in persons receiving the drug therapeutically, 100-300 μg/L in those arrested for impaired driving and 300-2000 μg/L in victims of acute overdosage. Most commercial immunoassays for the benzodiazepine class of drugs will cross-react with alprazolam, but confirmation and quantitation is usually performed using chromatographic techniques.
Alprazolam is classed as a high-potency benzodiazepine and is a triazolobenzodiazepine more specifically–a benzodiazepine with a triazole ring attached to its structure. Benzodiazepines produce a variety of therapeutic and adverse effects by binding to the benzodiazepine receptor site on the GABAA receptor and modulating the function of the GABA receptor, the most prolific inhibitory receptor within the brain. The GABA chemical and receptor system mediates inhibitory or calming effects of alprazolam on the nervous system. The GABAA receptor is made up of 5 subunits out of a possible 19, and GABAA receptors made up of different combinations of subunits have different properties, different locations within the brain, and, importantly, different activities with regard to benzodiazepines. Benzodiazepines and in particular alprazolam causes a marked suppression of the hypothalamicpituitary-adrenal axis. The therapeutic properties of alprazolam are similar to other benzodiazepines and include anxiolytic, anticonvulsant, muscle relaxant, hypnotic and amnesic.
Alprazolam is readily absorbed from the gastrointestinal tract with a bioavailability of 80–100%. The peak plasma concentration is achieved in 1–2 hours. Most of the drug is bound to plasma protein, mainly serum albumin. Alprazolam is hydroxylated in the liver to α-hydroxyalprazolam, which is also pharmacologically active but much less so than the parent compound. This and other metabolites are later excreted in urine as glucuronides. Some of the drug is also excreted in unchanged form. The elderly clear alprazolam more slowly than younger adults.
Alprazolam is a chemical analog of triazolam that differs by the absence of a chlorine atom in the o-position of the 6-phenyl ring. The same scheme that was used to make triazolam can be used to make alprazolam, with the exception that it begins with 2-amino-5-chlorobenzophenone. However, a non-standard way of making alprazolam has been suggested, which comes from 2,6-dichloro-4-phenylquinoline, the reaction of which with hydrazine gives 6-chloro-2-hydrazino-4-phenylquinoline. Boiling this with triethyl orthoacetate in xylene leads to the heterocyclization into a triazole derivative. The resulting product undergoes oxidative cleavage using sodium periodate and ruthenium dioxide in an acetone–water system to give 2-[4-(3′-methyl-1,2,4-triazolo)]-5-chlorobenzophenone. Oxymethylation of the last using formaldehyde and subsequent substitution of the resulting hydroxyl group by phosphorus tribromide,gives 2-[4-(3′-methyl-5′-bromomethyl-1,2,4-triazolo)]-5-chlorobenzophenone. Substitution of the bromine atom with an amino group using ammonia and the spontaneous, intramolecular heterocyclization following that reaction gives alprazolam.
Alprazolam was first released by Upjohn (now a part of Pfizer). It is covered under U.S. Patent 3,987,052, which was filed on October 29, 1969, granted on October 19, 1976, and expired in September 1993. Alprazolam was released in 1981. The first approved indication was panic disorder. Upjohn took this direction at the behest of a young psychiatrist, David Sheehan. Sheehan's suggestion was to use the new distinction the DSM-III created in the classification of anxiety disorders between generalized anxiety disorder (GAD) and panic disorder in order to market alprazolam specifically for the latter.[clarification needed] Panic disorder was, at that point, perceived to be rare and treatable only with tricyclic antidepressants; benzodiazepines were thought to be ineffective.
However, from his clinical experience, Sheehan knew panic disorder to be both widespread among the populace and responsive to benzodiazepines. He suggested to Upjohn that marketing alprazolam for panic disorder would both cover new diagnostic territory and emphasize the unique potency of this drug. Sheehan describes the first group of patients treated by alprazolam as so impressed by its action that the company knew outright that the drug was going to be a hit. A few of those patients actually pooled their money and purchased stock in Upjohn. Several months later, when alprazolam was approved by the United States Food and Drug Administration, they sold out and made a profit.[clarification needed]
Soon after its introduction a number of case reports were published in the medical literature of severe withdrawal symptoms, including psychoses, seizures and intense rebound anxiety, upon discontinuation of alprazolam. Several studies found that initial treatment of panic disorder with alprazolam was significantly superior but after 8 weeks of use alprazolam lost its effectiveness and was no more effective than placebo. It was found[by whom?] that behavioral therapy and the drug imipramine however, proved superior to both placebo and alprazolam. It has been argued[by whom?] that placebo is superior than alprazolam after 8 weeks of use due to lack of rebound withdrawal effects and side effects. Controversy exists in that there are allegations that the drug manufacturer suppressed these negative findings regarding lack of sustained efficacy.
Society and culture
Most prescribed alprazolam users do not misuse their medication, and the long-term use of benzodiazepines doesn't generally collaborate with the need for dose escalation. However, based on US findings from the Treatment Episode Data Set (TEDS), an annual compilation of patient characteristics in substance abuse treatment facilities in the United States, admissions due to "primary tranquilizer" (including, but not limited to, benzodiazepine-type) drug use increased 79% from 1992 to 2002, suggesting that misuse of benzodiazepines may be on the rise.
Alprazolam is one of the most commonly prescribed and misused benzodiazepines in the United States. A large-scale nationwide U.S. government study conducted by SAMHSA found that, in the U.S., benzodiazepines are recreationally the most frequently used pharmaceuticals due to their widespread availability, accounting for 35% of all drug-related visits to hospital emergency and urgent care facilities. Men use benzodiazepines recreationally as commonly as women. The report found that alprazolam is the most common benzodiazepine for recreational use followed by clonazepam, lorazepam, and diazepam.
Alprazolam, along with other benzodiazepines, is often used with other recreational drugs. These uses include aids to relieve the panic or distress of dysphoric ("bad trip") reactions to psychedelic drugs, such as LSD, and is often used in the "comedown" stages of stimulant use, such as amphetamine, in order to help relieve drug-induced agitation and insomnia, allowing sleep. Alprazolam may also be used in conjunction with other depressant drugs, such as alcohol, marijuana, heroin or other opiates, in an attempt to enhance the psychological effect of these drugs.
The poly-drug use of powerful depressant drugs poses the highest level of health concerns due to a significant increase in the likelihood of experiencing an overdose which may result in fatal respiratory depression.
A 1990 study claimed that diazepam has a higher misuse potential relative to other benzodiazepines, and that some data suggests that alprazolam and lorazepam resemble diazepam in this respect.
Anecdotally injection of alprazolam has been reported, causing dangerous damage to blood vessels, closure of blood vessels (embolization) and decay of muscle tissue (rhabdomyolysis). Alprazolam is practically not soluble in water, when crushed in water it will not fully dissolve (40 µg/ml of H2O at pH 7). There have also been anecdotal reports of alprazolam being snorted. Due to the low weight of a dose, alprazolam in one case was found to be distributed on blotter paper in a manner similar to LSD.
Alprazolam instant release (IR) is available in 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg strength regular and orally disintegrating tablets. Alprazolam Extended Release (XR) is available in 0.5 mg, 1 mg, 2 mg, and 3 mg strength oral.
Alprazolam is available in English-speaking countries under the following brand names:
In the United States, alprazolam is a prescription drug and is assigned to Schedule IV of the Controlled Substances Act by the Drug Enforcement Administration. Under the UK drug misuse classification system benzodiazepines are class C drugs (Schedule 4). In the UK, alprazolam is not available on the NHS and can only be obtained on private prescription. Internationally, alprazolam is included under the United Nations Convention on Psychotropic Substances as Schedule IV. In Ireland, alprazolam is a Schedule 4 medicine. In Sweden, alprazolam is a prescription drug in List IV (Schedule 4) under the Narcotics Drugs Act (1968). In the Netherlands, alprazolam is a List 2 substance of the Opium Law and is available for prescription.
- ^ First DataBank (July 2008). "Xanax (Alprazolam) clinical pharmacology - prescription drugs and medications at RxList". RxList. http://www.rxlist.com/xanax-drug.htm#cp.
- ^ First DataBank (July 2008). "Xanax XR (Alprazolam) clinical pharmacology - prescription drugs and medications at RxList". RxList. http://www.rxlist.com/xanax-xr-drug.htm#cp.
- ^ a b c Work Group on Panic Disorder (January 2009). "APA Practice Guideline for the Treatment of Patients With Panic Disorder, Second Edition". http://www.psychiatryonline.com/pracGuide/PracticePDFs/PanicDisorder_2e_PracticeGuideline.pdf. Retrieved 07/12/09.
- ^ a b c d FDA (23rd). "FDA approved labeling for Xanax revision08/23/2011" (PDF). Federal Drug Administration. p. 4. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018276s045lbl.pdf. Retrieved 14 September 2011. "Anxiety Disorders - XANAX Tablets (alprazolam) are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSMIII-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic... Panic Disorder - XANAX is also indicated for the treatment of panic disorder, with or without agoraphobia... Demonstrations of the effectiveness of XANAX by systematic clinical study are limited to 4 months duration for anxiety disorder and 4 to 10 weeks duration for panic disorder; however, patients with panic disorder have been treated on an open basis for up to 8 months without apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient."
- ^ a b Mandrioli, R.; Mercolini, L.; Raggi, M. A. (2008). "Benzodiazepine metabolism: An analytical perspective". Current drug metabolism 9 (8): 827–844. PMID 18855614.
- ^ Sheehan, D. V.; Sheehan, K. H.; Raj, B. A. (2007). "The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder". Psychopharmacology bulletin 40 (2): 63–81. PMID 17514187.
- ^ Smith, R. B.; Kroboth, P. D.; Vanderlugt, J. T.; Phillips, J. P.; Juhl, R. P. (1984). "Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration". Psychopharmacology 84 (4): 452–456. PMID 6152055.
- ^ a b c d e Verster JC, Volkerts ER. (2004). "Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature". CNS Drug Rev. 10 (1): 45–76. doi:10.1111/j.1527-3458.2004.tb00003.x. PMID 14978513. http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00003.x/pdf.
- ^ Penland, editor-in-chief, Rajesh R. Tampi ; associate editors, Sunanda Muralee, Natalie D. Weder ; assistant editor, Heath (2008). Comprehensive review of psychiatry. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health. pp. 226. ISBN 9780781771764. http://books.google.ca/books?id=AANMupaUs6UC&pg=PA226.
- ^ a b Pavuluri, Philip G. Janicak, Stephen R. Marder, Mani N. (2010). Principles and practice of psychopharmacotherapy (5th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. pp. 535. ISBN 9781605475653. http://books.google.ca/books?id=_ePK9wwcQUMC&pg=PA535.
- ^ a b Galanter, Marc (1 July 2008). The American Psychiatric Publishing Textbook of Substance Abuse Treatment (American Psychiatric Press Textbook of Substance Abuse Treatment) (American Psychiatric ... Press Textbook of Substance Abuse Treatment) (4 ed.). American Psychiatric Publishing, Inc.. p. 222. ISBN 978-1-58562-276-4. http://books.google.com/?id=6wdJgejlQzYC.
- ^ Forbes. "The most prescibed drugs in the US". http://www.forbes.com/2010/05/10/narcotic-painkiller-vicodin-business-healthcare-popular-drugs_slide_9.html. Retrieved 9 February 2009.
- ^ a b c United States Government; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (2006). "Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits". Substance Abuse and Mental Health Services Administration. http://dawninfo.samhsa.gov/files/ed2006/DAWN2k6ED.htm. Retrieved 9 February 2009.
- ^ a b c "Alprazolam". The American Society of Health-System Pharmacists. http://www.drugs.com/monograph/alprazolam.html. Retrieved 3 April 2011.
- ^ accessdate 1.October 2011 "DEA brief Benzodiazepines". http://www.justice.gov/dea/concern/b.html#2%7C accessdate 1.October 2011. "Given the millions of prescriptions written for benzodiazepines (about 100 million in 1999), relatively few individuals increase their dose on their own initiative or engage in drug-seeking behavior."
- ^ a b First DataBank (July 2008). "Xanax (Alprazolam) clinical pharmacology - prescription drugs and medications at RxList". RxList. http://www.rxlist.com/xanax-drug.htm.
- ^ Bandelow, B.; Zohar, J.; Hollander, E.; Kasper, S.; Möller, H. J.; World Federation Of Societies Of Biological Psychiatry Task Force On Treatment Guidelines For Anxiety, O. C. P. S. D. (2002). "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders". The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 3 (4): 171–199. PMID 12516310.
- ^ NetDoctor (October 1, 2006). "Xanax". netdoctor.co.uk. http://www.netdoctor.co.uk/medicines/100002807.html. Retrieved 2 August 2007.
- ^ The British National Formulary (2007). "Alprazolam". BNF. http://www.bnf.org/bnf/bnf/current/3173.htm. Retrieved 2 August 2007.
- ^ Lydiard, Rb; Laraia, Mt; Ballenger, Jc; Howell, Ef (May 1987). "Emergence of depressive symptoms in patients receiving alprazolam for panic disorder". The American journal of psychiatry 144 (5): 664–5. PMID 3578580.
- ^ "Xanax (Alprazolam) Drug Information: Uses, Side Effects, Drug Interactions and Warnings". RxList.com. USA. July 2008. p. 4. http://www.rxlist.com/xanax-drug.htm#wcp.
- ^ Iqbal, MM.; Sobhan, T.; Ryals, T. (Jan 2002). "Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant". Psychiatr Serv 53 (1): 39–49. doi:10.1176/appi.ps.53.1.39. PMID 11773648. http://ps.psychiatryonline.org/cgi/content/full/53/1/39.
- ^ García-Algar, Ó.; López-Vílchez, M. Á.; Martín, I.; Mur, A.; Pellegrini, M.; Pacifici, R.; Rossi, S.; Pichini, S. (2007). "Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis". Clinical Toxicology 45 (3): 295–298. doi:10.1080/15563650601072191. PMID 17453885.
- ^ Einarson, A.; Selby, P.; Koren, G. (January 2001). "Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling" (PDF). Journal of Psychiatry and Neuroscience 26 (1): 44–48. PMC 1408034. PMID 11212593. http://www.cma.ca/multimedia/staticContent/HTML/N0/l2/jpn/vol-26/issue-1/pdf/pg44.pdf.
- ^ Oo, C. Y.; Kuhn, R. J.; Desai, N.; Wright, C. E.; McNamara, P. J. (1995). "Pharmacokinetics in lactating women: Prediction of alprazolam transfer into milk". British journal of clinical pharmacology 40 (3): 231–236. PMC 1365102. PMID 8527284. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1365102.
- ^ a b "Alprazolam - Oral (Xanax) Side Effects, Medical Uses, and drug Interactions". MedicineNet.com. July 2005. http://www.medicinenet.com/alprazolam-oral/article.htm. Retrieved December 7, 2008.
- ^ "Xanax (Alprazolam) Drug Information: Uses, Side Effects, Drug Interactions and Warnings". RxList.com. DataBank, Inc. July 2008. p. 8. http://www.rxlist.com/cgi/generic/alpraz_wcp.htm. Retrieved December 7, 2008.
- ^ Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, AA.; Vennat, B.; Llorca, PM. et al. (November 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Ann Pharm Fr 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
- ^ a b Hori A. (February 1998). "Pharmacotherapy for personality disorders". Psychiatry and clinical neurosciences. 52 (1): 13–9. doi:10.1111/j.1440-1819.1998.tb00967.x. PMID 9682928.
- ^ Gardner DL, Cowdry RW (January 1985). "Alprazolam-induced dyscontrol in borderline personality disorder". Am J Psychiatry 142 (1): 98–100. PMID 2857071.
- ^ "Alprazolam". British National Formulary. 2007. http://www.bnf.org/bnf/bnf/current/3173.htm. Retrieved 3 August 2007.
- ^ mentalhealth.com (2007). "Alprazolam". http://www.mentalhealth.com/drug/p30-x01.html. Retrieved 3 August 2007.
- ^ Kozená L; Frantik E, Horváth M. (May 1995). "Vigilance impairment after a single dose of benzodiazepines". Psychopharmacology (Berl). 119 (1): 39–45. doi:10.1007/BF02246052. PMID 7675948.
- ^ a b Rawson, N. S.; Rawson, M. J. (1999). "Acute Adverse Event Signalling Scheme Using the Saskatchewan Administrative Health Care Utilization Datafiles: Results for Two Benzodiazepines". Canadian Journal of Clinical Pharmacology 6 (3): 159–66. PMID 10495368.
- ^ a b "Alprazolam – Complete Medical Information Regarding This Treatment of Anxiety Disorders". MedicineNet.com. http://www.medicinenet.com/alprazolam/article.htm. Retrieved August 2, 2007.
- ^ a b c Michel, L.; Lang, J. P. (2003). "Benzodiazepines and Forensic Aspects" (in French). Encephale 29 (6): 479–85. PMID 15029082. http://www.masson.fr/masson/MDOI-ENC-12-2003-29-6-0013-7006-101019-ART2.
- ^ Kravitz, H. M.; Fawcett, J.; Newman, A. J. (October 1993). "Alprazolam and Depression: A Review of Risks and Benefits". Journal of Clinical Psychiatry 54 (Supplement): 78–84; discussion 85. PMID 8262892.
- ^ a b "Alprazolam Side Effects, Interactions and Information". Drugs.com. http://www.drugs.com/alprazolam.html. Retrieved August 2, 2007.
- ^ "Complete Alprazolam Information". Drugs.com. http://alprazolam.drugs.com/. Retrieved 2 August 2007.
- ^ Cassano, G. B.; Toni, C.; Petracca, A.; et al. (March 1994). "Adverse Effects Associated with the Short-term Treatment of Panic Disorder with Imipramine, Alprazolam or Placebo". European Neuropsychopharmacology 4 (1): 47–53. doi:10.1016/0924-977X(94)90314-X. PMID 8204996.
- ^ a b Barbee, Jg (October 1993). "Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives". The Journal of clinical psychiatry 54 (Suppl): 86–97; discussion 98–101. PMID 8262893.
- ^ "ALPRAZOLAM - ORAL (Xanax) side effects, medical uses, and drug interactions.". medicinenet.com. http://www.medicinenet.com/alprazolam-oral/article.htm. Retrieved 2 August 2007.
- ^ Elie, R.; Lamontagne, Y. (June 1984). "Alprazolam and Diazepam in the Treatment of Generalized Anxiety". Journal of Clinical Psychopharmacology 4 (3): 125–129. doi:10.1097/00004714-198406000-00002. PMID 6145726.
- ^ Noyes, R.; DuPont, R. L.; Pecknold, J. C.; et al. (May 1988). "Alprazolam in Panic Disorder and Agoraphobia: Results from a Multicenter Trial. II. Patient acceptance, side effects, and safety". Arch. Gen. Psychiatry 45 (5): 423–428. PMID 3358644.
- ^ Béchir, M.; Schwegler, K.; Chenevard, R.; et al. (July 2007). "Anxiolytic Therapy with Alprazolam Increases Muscle Sympathetic Activity in Patients with Panic Disorders". Autonymous Neuroscience 134 (1–2): 69–73. doi:10.1016/j.autneu.2007.01.007. PMID 17363337. http://linkinghub.elsevier.com/retrieve/pii/S1566-0702(07)00008-2.
- ^ Rapaport, M.; Braff, D. L. (January 1985). "Alprazolam and Hostility". American Journal of Psychiatry 142 (1): 146. PMID 2857070.
- ^ Arana, G. W.; Pearlman, C.; Shader, R. I. (March 1985). "Alprazolam-induced Mania: Two Clinical Cases". American Journal of Psychiatry 142 (3): 368–369. PMID 2857534.
- ^ Strahan, A.; Rosenthal J.; Kaswan, M.; Winston, A. (July 1985). "Three Case Reports of Acute Paroxysmal Excitement Associated with Alprazolam Treatment". American Journal of Psychiatry 142 (7): 859–861. PMID 2861755. http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=2861755.
- ^ Reddy, J.; Khanna, S.; Anand, U.; Banerjee, A. (August 1996). "Alprazolam-induced Hypomania". Australia and New Zealand Journal of Psychiatry 30 (4): 550–552. doi:10.3109/00048679609065031. PMID 8887708.
- ^ Otani, K. (2003). "[Cytochrome P450 3A4 and Benzodiazepines]". Seishin Shinkeigaku Zasshi 105 (5): 631–42. PMID 12875231.
- ^ Dresser, GK.; Spence, JD.; Bailey, DG. (Jan 2000). "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition". Clin Pharmacokinet 38 (1): 41–57. doi:10.2165/00003088-200038010-00003. PMID 10668858.
- ^ a b Greenblatt, Dj; Wright, Ce (June 1993). "Clinical pharmacokinetics of alprazolam. Therapeutic implications". Clinical pharmacokinetics 24 (6): 453–71. doi:10.2165/00003088-199324060-00003. PMID 8513649.
- ^ Wang JS, DeVane CL (2003). "Pharmacokinetics and drug interactions of the sedative hypnotics" (PDF). Psychopharmacol Bull 37 (1): 10–29. doi:10.1007/BF01990373. PMID 14561946. http://www.medworksmedia.com/psychopharmbulletin/pdf/12/010-029_PB%20W03_Wang_final.pdf.
- ^ "FDA SPL Approved Application Filing for NDC Code 0228-3083 (Alprazolam by Actavis Elizabeth LLC)". AD535DF9-6361-460D-9648-450A0A6F61CD.xml.
- ^ Back DJ; Orme ML. (June 1990). "Pharmacokinetic drug interactions with oral contraceptives". Clin Pharmacokinet. 18 (6): 472–84. doi:10.2165/00003088-199018060-00004. PMID 2191822.
- ^ Izzo, AA.; Ernst, E. (2001). "Interactions between herbal medicines and prescribed drugs: a systematic review". Drugs 61 (15): 2163–75. doi:10.2165/00003495-200161150-00002. PMID 11772128.
- ^ Izzo, AA. (Mar 2004). "Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence". Int J Clin Pharmacol Ther 42 (3): 139–48. PMID 15049433.
- ^ Madabushi, R.; Frank, B.; Drewelow, B.; Derendorf, H.; Butterweck, V. (Mar 2006). "Hyperforin in St. John's wort drug interactions". Eur J Clin Pharmacol 62 (3): 225–33. doi:10.1007/s00228-006-0096-0. PMID 16477470.
- ^ Izzo, AA.; Ernst, E. (2009). "Interactions between herbal medicines and prescribed drugs: an updated systematic review". Drugs 69 (13): 1777–98. doi:10.2165/11317010-000000000-00000. PMID 19719333.
- ^ Isbister GK, O'Regan L, Sibbritt D, Whyte IM (July 2004). "Alprazolam is relatively more toxic than other benzodiazepines in overdose". Br J Clin Pharmacol 58 (1): 88–95. doi:10.1111/j.1365-2125.2004.02089.x. PMC 1884537. PMID 15206998. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1884537.
- ^ Wolf BC, Lavezzi WA, Sullivan LM, Middleberg RA, Flannagan LM (2005). "Alprazolam-related deaths in Palm Beach County". Am J Forensic Med Pathol 26 (1): 24–7. doi:10.1097/01.paf.0000153994.95642.c1. PMID 15725773.
- ^ a b Stahl, Stephen (1996). Essential Pharmacology: Neuroscientific Basis and Practical Applications. Cambridge: Cambridge University Press. ISBN 0-521-42620-0.
- ^ Juergens, Sm; Morse, Rm (May 1988). "Alprazolam dependence in seven patients". The American journal of psychiatry 145 (5): 625–7. PMID 3258735.
- ^ Klein, E (2002). "The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam". The Journal of clinical psychiatry 63 (Suppl 14): 27–33. PMID 12562116.
- ^ Professor Heather Ashton (2002). "The Ashton Manual – Benzodiazepines: How They Work and How to Withdraw". benzo.org.uk. http://www.benzo.org.uk/manual/. Retrieved 2008-10-31.
- ^ Closser, M. H.; Brower, K. J. (1994). "Treatment of alprazolam withdrawal with chlordiazepoxide substitution and taper". Journal of substance abuse treatment 11 (4): 319–323. PMID 7966502.
- ^ Romach, M. K.; Somer, G. R.; Sobell, L. C.; Sobell, M. B.; Kaplan, H. L.; Sellers, E. M. (1992). "Characteristics of long-term alprazolam users in the community". Journal of clinical psychopharmacology 12 (5): 316–321. PMID 1479048.
- ^ Fyer AJ; Liebowitz MR, Gorman JM, Campeas R, Levin A, Davies SO, Goetz D, Klein DF (March 1987). "Discontinuation of Alprazolam Treatment in Panic Patients". Am J Psychiatry (benzo.org.uk) 144 (3): 303–8. PMID 3826428. http://www.benzo.org.uk/alprazolam.htm. Retrieved 10 December 2008.
- ^ Breier, A.; Charney, D. S.; Nelson, J. C. (1984). "Seizures induced by abrupt discontinuation of alprazolam". The American journal of psychiatry 141 (12): 1606–1607. PMID 6150649.
- ^ Noyes Jr, R.; Perry, P. J.; Crowe, R. R.; Coryell, W. H.; Clancy, J.; Yamada, T.; Gabel, J. (1986). "Seizures following the withdrawal of alprazolam". The Journal of nervous and mental disease 174 (1): 50–52. PMID 2867122.
- ^ Levy, A. B. (1984). "Delirium and seizures due to abrupt alprazolam withdrawal: Case report". The Journal of clinical psychiatry 45 (1): 38–39. PMID 6141159.
- ^ Schatzberg, Alan; DeBattista, Charles (2003). Manual of Clinical Psychopharmacology. Washington, DC: American Psychiatric Pub.. pp. 391. ISBN 1-58562-209-5. http://bks4.books.google.mw/books?id=D3zz1NCm3qcC&pg=391#v=onepage&q&f=false.
- ^ a b Wolf, B.; Griffiths, R. R. (December 1991). "Physical Dependence on Benzodiazepines: Differences Within the Class". Drug and Alcohol Dependency 29 (2): 153–6. doi:10.1016/0376-8716(91)90044-Y. PMID 1686752. http://linkinghub.elsevier.com/retrieve/pii/0376-8716(91)90044-Y.
- ^ Higgitt, A; Fonagy, P; Lader, M (1988). "The natural history of tolerance to the benzodiazepines". Psychological medicine. Monograph supplement 13: 1–55. doi:10.1017/S0264180100000412. PMID 2908516.
- ^ Professor Heather Ashton (August 2002). "The Ashton Manual - Benzodiazepines: How They Work and How to Withdraw". http://www.benzo.org.uk/manual/.
- ^ Jones, A. W.; Holmgren, A.; Kugelberg, F. C. (2007). "Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results". Ther. Drug Monit. 29 (2): 248–260. doi:10.1097/FTD.0b013e31803d3c04. PMID 17417081.
- ^ Fraser, A. D.; Bryan, W. (1991). "Evaluation of the Abbott ADx and TDx serum benzodiazepine immunoassays for analysis of alprazolam". J. Anal. Toxicol. 15 (2): 63–65. PMID 1675703.
- ^ Baselt, R. (2011). Disposition of Toxic Drugs and Chemicals in Man (9th ed.). Seal Beach, CA: Biomedical Publications. pp. 45–48. ISBN 978-0-9626523-8-7.
- ^ Skelton KH; Nemeroff CB, Owens MJ (October 20, 2004). "Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression". J Neurosci 24 (42): 9303–12. doi:10.1523/JNEUROSCI.1737-04.2004. PMID 15496666.
- ^ Chouinard G (2004). "Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound". J Clin Psychiatry 65 (Suppl 5): 7–12. PMID 15078112. http://article.psychiatrist.com/?ContentType=START&ID=10000770.
- ^ White, G; Gurley, Da (February 1995). "Alpha subunits influence Zn block of gamma 2 containing GABAA receptor currents". Neuroreport 6 (3): 461–4. doi:10.1097/00001756-199502000-00014. PMID 7766843.
- ^ Arvat, E.; Giordano, R.; Grottoli, S.; Ghigo, E. (Sep 2002). "Benzodiazepines and anterior pituitary function". J Endocrinol Invest 25 (8): 735–47. PMID 12240908.
- ^ H.B. Jackson, U.S. Patent 3,987,052 (1976)
- ^ H.B. Jackson, DE 2012190 (1970)
- ^ Hester, J; Duchamp, David J.; Chidester, Connie G. (1971). "A synthetic approach to new 1,4-benzodiazepine derivatives". Tetrahedron Letters 12 (20): 1609. doi:10.1016/S0040-4039(01)87414-1.
- ^ Walser, A.; Zenchoff, G. (1977). "Quinazolines and 1,4-benzodiazepines. 81. S-Triazolo[4,3-a][1,4]benzodiazepines by oxidative cyclization of hydrazones". Journal of Medicinal Chemistry 20 (12): 1694. doi:10.1021/jm00222a035. PMID 592339.
- ^ J. Hester, U.S. Patent 3,709,898 (1972)
- ^ J. Hester, U.S. Patent 3,781,289 (1973)
- ^ Walker, Sydney (3 December 1996). A dose of sanity: mind, medicine, and misdiagnosis. New York: John Wiley & Sons. pp. 64–65. ISBN 978-0-471-19262-6. http://books.google.com/?id=1H_jx9XO4dcC&pg=PA65.
- ^ Healy, David (2000). The Psychopharmacologists, Vol. III: Interviews. London, UK: Arnold. pp. 479–504. ISBN 0-340-76110-5.
- ^ Walker, Sydney (3 December 1997). A Dose of Sanity: Mind, Medicine, and Misdiagnosis. New York: Wiley Sons. pp. 65–74. ISBN 978-0-471-19262-6. http://books.google.com/?id=1H_jx9XO4dcC.
- ^ McNally, Richard J. (1994). Panic Disorder: a Critical Analysis. New York, USA: Guilford Press. pp. 93–99. ISBN 978-0-89862-263-8. http://books.google.com/?id=SlUl5oTQIHoC.
- ^ Soumerai SB, Simoni-Wastila L, Singer C, et al. (July 2003). "Lack of relationship between long-term use of benzodiazepines and escalation to high dosages". Psychiatr Serv 54 (7): 1006–11. doi:10.1176/appi.ps.54.7.1006. PMID 12851438. http://ps.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=12851438.
- ^ Licata, S. C.; Rowlett, J. K. (2008). "Abuse and Dependence Liability of Benzodiazepine-Type Drugs: GABAA Receptor Modulation and Beyond". Pharmacology Biochemistry and Behavior 90 (1): 74–89. doi:10.1016/j.pbb.2008.01.001. PMC 2453238. PMID 18295321. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2453238.
- ^ Ballenger, J. C. (1984). "Psychopharmacology of the anxiety disorders". The Psychiatric clinics of North America 7 (4): 757–771. PMID 6151647.
- ^ Ciraulo, D. A.; Barnhill, J. G.; Greenblatt, D. J.; Shader, R. I.; Ciraulo, A. M.; Tarmey, M. F.; Molloy, M. A.; Foti, M. E. (1988). "Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men". The Journal of clinical psychiatry 49 (9): 333–337. PMID 3417618.
- ^ Vorma, H; Naukkarinen, Hh; Sarna, Sj; Kuoppasalmi, Ki (2005). "Predictors of benzodiazepine discontinuation in subjects manifesting complicated dependence". Substance use & misuse 40 (4): 499–510. doi:10.1081/JA-200052433. PMID 15830732.
- ^ Walker, Bm; Ettenberg, A (April 2003). "The effects of alprazolam on conditioned place preferences produced by intravenous heroin". Pharmacology, biochemistry, and behavior 75 (1): 75–80. doi:10.1016/S0091-3057(03)00043-1. PMID 12759115.
- ^ Wright State University and the University of Akron (January 2008). "OSAM - O- GRAM Highlights of Statewide Drug Use Trends" (PDF). USA: Ohio Government. http://www.odadas.state.oh.us/WebManager/UltimateEditorInclude/UserFiles/WebDocuments/Planning/Jan05ExecSummry.pdf. Retrieved 10 December 2008.
- ^ Griffiths RR, Wolf B (August 1990). "Relative abuse liability of different benzodiazepines in drug abusers". J Clin Psychopharmacol 10 (4): 237–43. doi:10.1097/00004714-199008000-00002. PMID 1981067.
- ^ Eric C; Wang, Felix S, Chew. (2006). "MR Findings of Alprazolam Injection into the Femoral Artery with Microembolization and Rhabdomyolysis" (PDF). Radiology Case Reports 1 (3). http://www.radiologycasereports.net/index.php/rcr/article/viewPDFInterstitial/33/187.
- ^ "DB00404 (Alprazolam)". Canada: DrugBank. August 26, 2008. http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD00280. Retrieved July 12, 2011.
- ^ Sheehan, M. F.; Sheehan, D. V.; Torres, A.; Coppola, A.; Francis, E. (1991). "Snorting benzodiazepines". The American journal of drug and alcohol abuse 17 (4): 457–468. PMID 1684083.
- ^ "Microgram bulletin". US DEA. http://www.justice.gov/dea/programs/forensicsci/microgram/mg0508/mg0508.html.
- ^ Merck Manual; Davis-Drug-Guide (5 February 2009). "alprazolam". Unbound Medicine. http://www.unboundmedicine.com/merckmanual/ub/view/Davis-Drug-Guide/51030/8/alprazolam. Retrieved 10 March 2009.
- ^ "Benzodiazepine Names". non-benzodiazepines.org.uk. http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html. Retrieved 2008-10-31.
- ^ "DEA, Drug Scheduling". DEA. http://www.usdoj.gov/dea/pubs/scheduling.html. Retrieved 2008-10-31.
- ^ UK Gov (1991). "Misuse of Drugs Act 1971 (c. 38)". The UK Statute Law database. http://www.statutelaw.gov.uk/content.aspx?LegType=All+Primary&PageNumber=56&NavFrom=2&parentActiveTextDocId=1367412&activetextdocid=1367464.
- ^ "4.1.2: Anxiolytics". British National Formulary (BNF 57). United Kingdom: BMJ Group and RPS Publishing. March 2009. p. 190. ISBN 978-0-85369-845-6.
- ^ International Narcotics Control Board (August 2003). "List of psychotropic substances under international control" (PDF). incb.org. http://www.incb.org/pdf/e/list/green.pdf. Retrieved 7 December 2008.
- ^ "Misuse Of Drugs (Amendment) Regulations". Irish Statute Book. Office of the Attorney General. 1993. http://www.irishstatutebook.ie/1993/en/si/0342.html.
- ^ ____284.aspx Narkotikaklassade läkemedel, Läkemedelsverket
Benzodiazepine derivatives 1,4-Benzodiazepines
Bromazepam · Camazepam · Carburazepam · Chlordiazepoxide · Cinolazepam · Clonazepam · Clorazepate · Cyprazepam · Delorazepam · Demoxepam · Devazepide * · Diazepam · Doxefazepam · Elfazepam · Ethyl carfluzepate · Ethyl dirazepate · Ethyl loflazepate · Fletazepam · Fludiazepam · Flunitrazepam · Flurazepam · Flutemazepam · Flutoprazepam · Fosazepam · Gidazepam · Halazepam · Iclazepam · Ketazolam · Lorazepam · Lormetazepam · Meclonazepam · Medazepam · Menitrazepam · Metaclazepam · Motrazepam · Nimetazepam · Nitrazepam · Nitrazepate · Nordazepam · Nortetrazepam · Oxazepam · Phenazepam · Pinazepam · Pivoxazepam · Prazepam · Proflazepam · Quazepam · QH-II-66 · Reclazepam · Ro5-2904 · Ro5-4864 * · Sulazepam · Temazepam · Tetrazepam · Tifluadom * · Tolufazepam · Tuclazepam · Uldazepam
1,5-Benzodiazepines 2,3-Benzodiazepines * Triazolobenzodiazepines Imidazobenzodiazepines Oxazolobenzodiazepines Thienodiazepines Pyridodiazepines
Lopirazepam · Zapizolam
Pyrazolodiazepines Pyrrolodiazepines Tetrahydroisoquinobenzodiazepines Benzodiazepine prodrugs* atypical activity profile (not GABAA receptor ligands) Anxiolytics (N05B) GABAA PAMsAdinazolam • Alprazolam • Bretazenil • Bromazepam • Camazepam • Chlordiazepoxide • Clobazam • Clonazepam • Clorazepate • Clotiazepam • Cloxazolam • Diazepam • Ethyl Loflazepate • Etizolam • Fludiazepam • Halazepam • Imidazenil • Ketazolam • Lorazepam • Medazepam • Nordazepam • Oxazepam • Pinazepam • PrazepamAbecarnil • Adipiplon • Alpidem • CGS-8216 • CGS-9896 • CGS-13767 • CGS-20625 • Divaplon • ELB-139 • Fasiplon • GBLD-345 • Gedocarnil • L-838,417 • NS-2664 • NS-2710 • Ocinaplon • Pagoclone • Panadiplon • Pipequaline • RWJ-51204 • SB-205,384 • SL-651,498 • Taniplon • TP-003 • TP-13 • TPA-023 • Y-23684 • ZK-93423PyrazolopyridinesOthers α2δ VDCC Blockers 5-HT1A Agonists H1 Antagonists CRH1 Antagonists NK2 AntagonistsGR-159,897 • Saredutant MCH1 antagonistsATC-0175 • SNAP-94847 mGluR2/3 Agonists mGluR5 NAMs TSPO agonists σ1 agonistsAfobazole • Opipramol Others
Wikimedia Foundation. 2010.
Look at other dictionaries:
Alprazolam — Général Nom IUPAC 8 chloro 1 methyl 6 phe … Wikipédia en Français
Alprazolam — Saltar a navegación, búsqueda Alprazolam … Wikipedia Español
alprazolam — benzodiazepina de segunda generación utilizada como sedante y en trastornos de angustia monografía [véase http://www.iqb.es/cbasicas/farma/farma04/a039.htm] Diccionario ilustrado de Términos Médicos.. Alvaro Galiano. 2010. alprazolam … Diccionario médico
Alprazolam — Strukturformel Allgemeines Freiname Alprazolam … Deutsch Wikipedia
Alprazolam — АЛЬПРАЗОЛАМ ( Alprazolam ). 8 Хлор 1 метил 6 фенил 4Н [1,2,4] триазоло[4,3а] [1,4] бензодиазепин. Синонимы: Альпракс, Ксанакс, Нейрол, Alprax, Cassadan, Frontal, Neurol, Prinax, Restil, Solanax, Tafil, Trankimazin, Tricca, Xanax, Xanor, Zotran.… … Словарь медицинских препаратов
alprazolam — noun Etymology: alprazol (perhaps from rearrangement of letters in triazole compound with a ring composed of two carbon and three nitrogen atoms and benzodiazepine) + am (as in diazepam) Date: 1973 a benzodiazepine tranquilizer C17H13ClN4 used… … New Collegiate Dictionary
alprazolam — /al pray zeuh lam /, n. Pharm. a potent benzodiazepine, C17H13CIN4, used in the treatment of certain anxiety states. [laboratory coinage of unexplained orig.] * * * … Universalium
alprazolam — noun An antianxiety drug 8 chloro 1 methyl 6 phenyl 4H [1,2,4]triazolo[4,3 a][1,4]benzodiazepine Syn: xanax, Xanax … Wiktionary
alprazolam — A benzodiazepine minor tranquilizer used for management of anxiety disorders and panic attack; abuse may lead to habituation or addiction. * * * al·praz·o·lam al praz ə .lam … Medical dictionary
alprazolam — [al preɪzə(ʊ)lam] noun Medicine a drug of the benzodiazepine group, used in the treatment of anxiety. Origin 1970s: from al of unknown origin + p(henyl) + (t)r(i)azol(e) + ( azep)am … English new terms dictionary